The FDA has taken action against numerous telehealth companies and drug makers, including Hims & Hers, by issuing over 100 warning letters. These warnings target these firms for promoting compounded versions of popular GLP‑1 weight-loss drugs with misleading claims. Authorities emphasize the importance of accurate marketing and safety in weight-loss treatments. The crackdown aims to protect consumers from false information and ensure responsible communication about pharmaceutical options.